Locations:
Search IconSearch
February 10, 2022/Cancer/Surgical Oncology

Bioimpedance Spectroscopy May Be Best Tool for Preventing Breast Cancer-Related Chronic Lymphedema

Low-strength electrical current identifies at-risk patients with greater accuracy than tape measurement

Cross section of human breast cross section. 3d illustration

Bioimpedance spectroscopy (BIS) coupled with early compression treatment appears to be more effective than tape measure-triggered compression for preventing lymphedema after breast cancer surgery. According to a recent international, multicenter study, BIS can identify patients who are likely to benefit from early compression intervention with greater precision than tape measurement (TM) alone. In addition, BIS is associated with a significant absolute reduction in chronic lymphedema in women with breast cancer.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The primary end point of the trial was the rate of chronic lymphedema using complex decongestive physiotherapy as a surrogate,” explains Cleveland Clinic radiation oncologist Chirag Shah, MD, a co-author of the randomized study. “Our data showed that there was a statistically significant reduction in chronic lymphedema when we used BIS to conduct prospective surveillance. Historically, approximately 20% of patients developed chronic lymphedema based on their need for complex decongestive physiotherapy, but BIS reduced that rate to only 7.9%.”

Mitigating the side effects of breast cancer treatment

In explaining the rationale behind this research, he emphasizes that lymphedema is a major potential side effect of breast cancer treatment that can have a profound impact on patients’ quality of life.

“Unfortunately, lymphedema is relatively common in patients with breast cancer, particularly in those with more advanced disease who require lymph node dissection, radiation therapy, and/or chemotherapy,” says Dr. Shah, Director of Clinical Research in the Department of Radiation Oncology at Taussig Cancer Institute. “Because the condition is associated with significant morbidity and quality-of-life-altering complications, we feel it is worthy of continuing research.”

According to Dr. Shah, the major driver of lymphedema is the amount of local/regional therapy that a patient receives for their breast cancer.

“There are several driving factors that increase the risk of lymphedema more than the patient’s age or the type of breast cancer itself,” he explains. “For example, women who require axillary lymph node dissection compared to sentinel lymph node biopsy suffer from higher rates of lymphedema, as do patients who require regional lymph node radiation. In addition, some forms of chemotherapy — such as taxane-based chemotherapy — are associated with a higher incidence of lymphedema.”

Advertisement

Comparing BIS to tape measurement

The multicenter, international trial enrolled 1,200 patients with newly diagnosed breast cancer between June 24, 2014 and September 11, 2018. All patients had undergone surgery for their cancer. Study subjects were randomized 1:1 to prospective surveillance by BIS (n=482) or tape measurement (n=442) and screened for lymphedema development at regular intervals for three years after breast cancer surgery. The rate of progression to chronic breast cancer-related lymphedema, following an intervention for subclinical lymphedema using a compression garment, served as the primary end point.

Dr. Shah notes that this is the first randomized trial to compare BIS to tape measurement as a method of breast cancer surveillance. In addition, it appears to be the largest study of early treatment for breast cancer-related lymphedema. “I don’t think there has ever been a similar study close to this size,” he says.

Approximately 14% of study participants progressed to chronic lymphedema after intervention with a compression garment; however, only 8% of patients in the BIS arm developed this complication compared to 19.2% in the tape-measurement group. Interestingly, the patients monitored with BIS also required fewer interventions/triggers than those in the tape-measurement group (20% vs. 28%).

These findings amount to an absolute reduction of 11.3% in the propensity to progress to chronic lymphedema with the use of BIS surveillance coupled with early intervention with a compression garment.

Importance of breast cancer surveillance

“These results imply that breast cancer patients who are at risk of developing lymphedema should undergo prospective lymphedema surveillance with BIS coupled with the early use of a compression garment,” Dr. Shah says, adding that the trial has shown BIS to be a far superior breast cancer-related lymphedema diagnostic technique as compared to tape measurement.

Advertisement

Related Articles

Hospice nurse with patient
March 10, 2026/Cancer/News & Insight

Centering End-of-Life Care Around What Matters Most

Goal-of-care discussions drive earlier hospice access

Dr. Lauren Kopicky headshot
March 4, 2026/Cancer/Podcast

Rethinking Axillary Management in Breast Cancer (Podcast)

Clinical trials and de-escalation strategies

Lobular breast cancer cells
February 26, 2026/Cancer/News & Insight

Standard of Care for Hormone-Sensitive Advanced Breast Cancer Also Effective for Lobular Subgroup

Combination therapy improves outcomes, but lobular patients still do worse overall than ductal counterparts

Person hugging in support group
February 25, 2026/Cancer/Patient Support

Treating Substance Use Disorder in Patients with Cancer

Bringing empathy and evidence-based practice to addiction medicine

Drs. Turk and Khatri headshots
February 23, 2026/Cancer/Podcast

Beyond Mammography (Podcast)

Supplemental screening for dense breasts

Dr. Elvin Zan headshot
February 17, 2026/Cancer/Podcast

Expanding Cancer Treatment with Theranostics (Podcast)

Combining advanced imaging with targeted therapy in prostate cancer and neuroendocrine tumors

Man touching lymph nodes
February 12, 2026/Cancer/News & Insight

EGFR-MET Bispecific Antibody Shows Promise for Metastatic Head & Neck Cancer

Early results show strong clinical benefit rates

Bispecific antibodies
February 10, 2026/Cancer/Blood Cancers

MajesTEC-3 Trial Outcomes May Change Course of Myeloma Treatment

The shifting role of cell therapy and steroids in the relapsed/refractory setting

Ad